{"id":44586,"date":"2019-12-05T00:00:00","date_gmt":"2019-12-04T23:00:00","guid":{"rendered":"https:\/\/techma.bakertilly.es\/amadix-biomedicina-contra-el-cancer\/"},"modified":"2025-03-12T11:49:14","modified_gmt":"2025-03-12T10:49:14","slug":"amadix-biomedicina-contra-el-cancer","status":"publish","type":"post","link":"https:\/\/techma.bakertilly.es\/en\/amadix-biomedicina-contra-el-cancer\/","title":{"rendered":"AMADIX: BIOMEDICINE AGAINST CANCER"},"content":{"rendered":"

Amadix, a Spanish biomedical company focused on products for the early detection of cancer, sells<\/a> part of its shares worth approximately \u20ac3.2 million.<\/p>\n

Of this, \u20ac1.2m has been structured through a crowdfunding operation.<\/p>\n

The rest has come from the company's shareholders such as CRB Inverb\u00edo and Inveready Capital.<\/p>\n

Oncology continues to be the therapeutic area with the highest number of investigations.<\/p>\n

This is a fact that can be seen in the number of movements that the sector generates in corporate finance.<\/p>\n

<\/span>MEETING AMADIX<\/span><\/h2>\n

It is a Spanish start-up, created in 2010, and specialising in biomedicine<\/strong>which provides focus on early detection of cancer<\/strong>.<\/p>\n

\"AMADIX:<\/p>\n

In fact, their products are blood tests to detect signs of a future tumour that is not yet present.<\/p>\n

This is a very different way of diagnosis from the usual way of diagnosing.<\/p>\n

It is currently focused on the early detection of this disease in the colon. Moreover, it is making steady progress in the commercialisation of a test to achieve this.<\/p>\n

The main objective of Amadix<\/a> is to commercialise this technology from 2020.<\/p>\n

<\/span>COLOFAST<\/span><\/h2>\n

This test is called Colofast<\/em>.<\/p>\n

After a normal blood draw, this solution performs a state-of-the-art biomarker analysis where it is able to differentiate between healthy and sick people.<\/p>\n

It is able to detect the tumour as pre-malignant lesions that appear before the tumour forms and up to 15 years before showing the first symptoms.<\/p>\n

If polyps are detected they are removed and disease does not develop.<\/p>\n

Colon cancer is very slow-growing, so if you are screened once a year, there is plenty of scope to tackle the disease even before it starts.<\/p>\n

In the coming months, Amadix will also work towards regulatory approval in Europe.<\/p>\n

This will ensure that the products to be placed on the market meet the requirements of the European Union.<\/p>\n

<\/span>SCREENING FOR OTHER CANCERS<\/span><\/h2>\n

In addition, the firm is conducting parallel research into how to detect lung cancer very early in healthy smokers with Diagnolung<\/em>as well as pancreatic cancer in asymptomatic individuals thanks to Pancreadix<\/em>.<\/p>\n

Both solutions, similar to Colofast, are in the clinical validation stage and have an undefined time to market.<\/p>\n

The company's main strength is the scientific basis of the products.<\/p>\n

For now,\u00a0the company has its sights set on the US and Europe, especially Spain.<\/strong>.<\/strong><\/p>\n

However, he does not rule out probing the Chinese market, where he sees a high growth potential.<\/p>\n

According to Roc\u00edo Arroyo, CEO of Amadix, \"more than fifteen million people at risk in Spain will be able to stay ahead of cancer\".<\/p>\n

<\/span>SEVERAL CAPITAL INCREASES<\/span><\/h2>\n

In order to meet the costs of this, it has put part of its shares up for sale in a round of 1,2M\u20ac<\/strong> through the crowdfunding platform The Crowd Angel<\/em><\/a>.<\/p>\n

This amount is the last section<\/strong> of a round of 3.2M\u20ac total<\/strong>.<\/p>\n

Amadix partners increased their shareholding in the company, contributing a total of 2,2M\u20ac<\/strong>.<\/p>\n

A<\/strong>These include, for example, the CRB investment network Inverb\u00edo, <\/strong>or venture capital funds such as Inveready.<\/strong><\/p>\n

In 2017, Amadix already achieved 2.8M\u20ac<\/strong> by obtaining assistance through the programme Horizon 2020<\/em>The European Commission.<\/p>\n

Subsequently, the company received more than half a million euros from Alentia, and was awarded by the South Summit as the best company of the year.\u00a0start up<\/em>\u00a0of the event in 2018.<\/p>\n

<\/span>OTHER IMPORTANT ROUNDS IN THE SECTOR<\/span><\/h2>\n

<\/span>MEDLUMICS<\/span><\/h3>\n

Medlumics is a Spanish company medical devices<\/strong> born in 2009.<\/p>\n

Its aim is to improve living standards for human beings through technology.<\/p>\n

To achieve this, it has recently been able to raise more than 3.5M\u20ac<\/strong> in its latest round of funding<\/a>.<\/p>\n

<\/span>VYTRUS BIOTECH<\/span><\/h3>\n

Vytrus biotech<\/a> was born as a company Spin Off<\/em> of the Faculty of Pharmacy of the University of Barcelona.<\/p>\n

Belonging to the plant biotechnology sector, it is specialising in the production of high-value active ingredients<\/strong>for use in the pharmaceutical and cosmetics sector.<\/p>\n

In order to continue its growth, last November it attracted more than 1.2M\u20ac<\/strong> in a Series A financing round.<\/p>","protected":false},"excerpt":{"rendered":"

We analyse from a corporate finance perspective the sale of shares in the biotech company Amadix, valued at around \u20ac3.2m.<\/p>","protected":false},"author":4,"featured_media":44587,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[1750],"tags":[155,153,157],"sectores":[],"tipo-contenido":[2260],"class_list":["post-44586","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-financiacion-sectorial","tag-corporate-finance-spain","tag-global-corporate-finance","tag-venta-de-empresas","tipo-contenido-noticias"],"acf":[],"_links":{"self":[{"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/posts\/44586","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/comments?post=44586"}],"version-history":[{"count":0,"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/posts\/44586\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/media\/44587"}],"wp:attachment":[{"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/media?parent=44586"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/categories?post=44586"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/tags?post=44586"},{"taxonomy":"sectores","embeddable":true,"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/sectores?post=44586"},{"taxonomy":"tipo-contenido","embeddable":true,"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/tipo-contenido?post=44586"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}